Yukti Choudhury, Director of Clinical Development at HistoIndex, joins Roger Green to discuss FibroSIGHT™, a new HistoIndex service that allows clinicians to use HistoIndex’s Second Harmonic Generation (SHG) technology to determine specific CRN fibrosis level for patients with inconclusive NIT results. Yukti states that demand for this technique could equal 163,000 cases this year and rise to one million by 2028. She provides practical cues on ordering the test and its reimbursement.

Roger shares his long-standing respect for SHG and the clarity it produces. He notes the economic benefit of determining whether a patient has F2 fibrosis, which is indicated for pharmacotherapy, vs.F1, which is not indicated. He sees clear benefit, but expresses concern that any option requiring more biopsies will reduce the number of patients treated.